Literature DB >> 21917010

VIM and IMP metallo-β-lactamases and other extended-spectrum β-lactamases in Escherichia coli and Klebsiella pneumoniae from environmental samples in a Tunisian hospital.

Chedly Chouchani1, Rim Marrakchi, Leila Ferchichi, Allaaeddin El Salabi, Timothy R Walsh.   

Abstract

An extremely drug-resistant Enterobacteriaceae species emerged in Kasserine Hospital, Tunisia between 2009 and 2010 causing a local outbreak. We aimed to characterize extended-spectrum β-lactamase (ESBL) and metallo-β-lactamase (MBL)-producing Enterobacteriaceae from the hospital environment. Swabs were collected from ten different wards from Kasserine Hospital, Tunisia. A total of 46 isolates were cultured onto MacConkey agar supplemented with ceftazidime to select for ESBL-producing Enterobacteriaceae. Identification and susceptibility patterns were performed using Phoenix-automated phenotypic identification criteria. Extended spectrum β-lactamases (ESBLs) were detected using cefepime ESBL E-test. Colony blotting was first used to detect the occurrence of bla(SHV) , bla(CTX-M) , bla(CMY) , bla(IMP) , and bla(VIM) genes. PCR was used to amplify these genes, and the amplicons were sequenced and analyzed. Total DNA was digested with XbaI, and PFGE was used to type the major isolates that produced IMP-1. Among the 46 isolates, 63% were Klebsiella pneumoniae, 13% were Escherichia coli, 8.7% were Proteus mirabilis, 6% were Enterobacter cloaceae, 4.3% were Providencia rettgeri, 2.5% were Serratia marcescens, and 2.5% were Pantoea agglomerans. PCR amplification and DNA sequencing showed that hospital environment isolates produced SHV-125, CTX-M-15, CMY-2 ESBLs, and IMP-1 and VIM-2 MBLs. PFGE typing showed the emergence of IMP-1 MBL-producing K. pneumoniae isolates that were not clonal. In this study, we report the first characterization of IMP-1 and VIM-2 MBL-producing K. pneumoniae and E. coli isolates collected from Kasserine Hospital, Tunisia.
© 2011 The Authors. APMIS © 2011 APMIS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917010     DOI: 10.1111/j.1600-0463.2011.02793.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

1.  Characterization of IncA/C conjugative plasmid harboring bla TEM-52 and bla CTX-M-15 extended-spectrum β-lactamases in clinical isolates of Escherichia coli in Tunisia.

Authors:  C Chouchani; A El Salabi; R Marrakchi; L Ferchichi; T R Walsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-22       Impact factor: 3.267

2.  Detection and characterization of VIM-31, a new variant of VIM-2 with Tyr224His and His252Arg mutations, in a clinical isolate of Enterobacter cloacae.

Authors:  Pierre Bogaerts; Carine Bebrone; Te-Din Huang; Warda Bouchahrouf; Yves Degheldre; Ariane Deplano; Kurt Hoffmann; Youri Glupczynski
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 3.  The spread of carbapenemase-producing bacteria in Africa: a systematic review.

Authors:  Rendani I Manenzhe; Heather J Zar; Mark P Nicol; Mamadou Kaba
Journal:  J Antimicrob Chemother       Date:  2014-09-26       Impact factor: 5.790

Review 4.  Past and Present Perspectives on β-Lactamases.

Authors:  Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 5.  Carbapenemase Producing Gram-Negative Bacteria in Tunisia: History of Thirteen Years of Challenge.

Authors:  Olfa Dziri; Raoudha Dziri; Allaaeddin Ali El Salabi; Chedly Chouchani
Journal:  Infect Drug Resist       Date:  2020-11-23       Impact factor: 4.003

6.  First Italian outbreak of VIM-producing Serratia marcescens in an adult polyvalent intensive care unit, August-October 2018: A case report and literature review.

Authors:  Maria Rosaria Iovene; Vincenzo Pota; Massimiliano Galdiero; Giusy Corvino; Federica Maria Di Lella; Debora Stelitano; Maria Beatrice Passavanti; Maria Caterina Pace; Aniello Alfieri; Sveva Di Franco; Caterina Aurilio; Pasquale Sansone; Vettakkara Kandy Muhammed Niyas; Marco Fiore
Journal:  World J Clin Cases       Date:  2019-11-06       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.